| CAS NO: | 142340-99-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 501.47 |
|---|---|
| Formula | C20H32N5O8P |
| CAS No. | 142340-99-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (199.4 mM) |
| Water:<1 mg/mL | |
| Ethanol: 100 mg/mL (199.4 mM) | |
| Other info | Chemical Name: [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate InChi Key: WOZSCQDILHKSGG-UHFFFAOYSA-N InChi Code: InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23) SMILES Code: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C |
| Synonyms | GS 0840; GS0840; GS-0840; Hepsera; Preveon. Adefobir; GS-0393; GS-393; GS0393; GS393; GS 0393; GS 393; PMEA |
| In Vitro | In vitro activity: Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil is used for treatment of hepatitis B and herpes simplex virus infection. |
|---|---|
| In Vivo | Adefovir Dipivoxil reduces Liver HBV DNA to<0.1 pg of viral DNA per mg of total DNA (pg/mg) in transgenic mice expressing hepatitis B virus. Adefovir Dipivoxil treatment also reduces serum HBV DNA to 3.5 log10 genomic equivalents (ge)/mL in transgenic mice expressing hepatitis B virus compared to 5.3 log10 ge/mL for the placebo control group. Adefovir Dipivoxil antiviral activity reaches near maximum viral reduction by day 10 in the liver and reaches an endpoint of liver virus inhibition at 1.0 mg/kg/day. |
| Animal model | Mice |
| Formulation & Dosage | 1.0 mg/kg/day. |
| References | Antiviral Res. 2002 Jul;55(1):27-40. |
m.cnreagent.com